Cited by 450Liver Disease Diagnosis and TreatmentLiver Diseases and ImmunityLiver physiology and pathology

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis

Open access

Musso, Giovanni, Cassader, Maurizio, Paschetta, Elena, Gambino, Roberto·2017·JAMA Internal Medicine

DOI 10.1001/jamainternmed.2016.9607PMC PMC5470366

Open this paper in CoChat — free account Open PDF

Abstract

Importance: Nonalcoholic steatohepatitis (NASH) is projected to be the leading cause of liver transplantation by 2020. Advanced fibrosis (stage F3-F4) on liver biopsy independently predicts all-cause and liver-related mortality in NASH. There are no known efficacious treatments for advanced fibrosis related to NASH. Thiazolidinedione therapy has been extensively evaluated in NASH, and new randomized clinical trials (RCTs) of its efficacy have been completed. Objective: To synthesize the evidence about the association of thiazolidinedione therapy with advanced liver fibrosis in NASH. Data Sources: MEDLINE, Ovid MEDLINE In-Process, Cochrane Library, EMBASE, clinicaltrials.gov, PubMed, and Scopus databases (without language restrictions), as well as other registries and scientific meeting presentations, from database inception through August 15, 2016. Study Selection: Randomized clinical trials evaluating the effect of thiazolidinedione therapy on histologic features of the liver in biopsy-proven NASH. Data Extraction and Synthesis: Two investigators extracted study data independently and in duplicate and rated the risk of bias using the Cochrane Risk of Bias Tool. Main Outcomes and Measures: The primary outcome was a dichotomous improvement in advanced fibrosis on liver biopsy, defined as an improvement in fibrosis stage from F3-F4 to F0-F2. Secondary outcomes were at least a 1-point improvement in fibrosis of any stage and NASH resolution. This meta-analysis also evaluated adverse effects of thiazolidinedione therapy, including weight gain, lower limb edema, congestive heart failure, bone fractures, cancer, and anemia. With the use of random-effects models, dichotomous variables are presented as odds ratios (ORs) with 95% CIs, and continuous variables are presented as weighted mean differences with 95% CIs. Results: This study analyzed 8 RCTs (5 evaluating pioglitazone use and 3 evaluating rosiglitazone maleate use) enrolling 516 patients with biopsy-proven NASH for a duration of 6 to 24 months. Among all studies combined, thiazolidinedione therapy was associated with improved advanced fibrosis (OR, 3.15; 95% CI, 1.25-7.93; P = .01; I2 = 0%), fibrosis of any stage (OR, 1.66; 95% CI, 1.12-2.47; P = .01; I2 = 0%), and NASH resolution (OR, 3.22; 95% CI, 2.17-4.79; P < .001; I2 = 0%). Analyses restricted to RCTs enrolling patients without diabetes yielded similar results for improvement in advanced fibrosis (OR, 2.95; 95% CI, 1.04-10.90; P = .02; I2 = 0%), improvement in fibrosis of any stage (OR, 1.76; 95% CI, 1.02-3.03; P = .02; I2 = 0%), and NASH resolution (OR, 3.40; 95% CI, 1.95-5.93; P < .001; I2 = 0%). All effects were accounted for by pioglitazone use. Weight gain and lower limb edema occurred more frequently with thiazolidinedione therapy (initial body weight +2.70%; 95% CI, 1.96%-4.34%; P = .001). The small sample size of included RCTs prevented evaluation of more serious adverse effects of thiazolidinedione therapy. Conclusions and Relevance: Pioglitazone use improves advanced fibrosis in NASH, even in patients without diabetes. Whether this finding translates to improvement in risk for clinical outcomes requires further study.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamainternmed.2016.9607

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,854
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States
Wong, R. J., Aguilar, M. E. F., Cheung, R. C., Perumpail, R. B., Harrison, S. A., Younossi, Z. M., & Ahmed, A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.11.039 · Cited by 1,861
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827

Show all 31 references

Sorted by citations

Items 201–300 of 450

Non-alcoholic fatty liver disease: Current therapeutic options
Majumdar, A., Verbeek, J., & Tsochatzis, E. A. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.09.007 · Cited by 26
Nonalcoholic Fatty Liver Disease and Its Complex Relation with Type 2 Diabetes Mellitus—From Prevalence to Diagnostic Approach and Treatment Strategies
Diaconu, C.-T., & Guja, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11175144 · Cited by 29
Salidroside in the Treatment of NAFLD/NASH
Qu, B., Liu, X., Liang, Y., Zheng, K., Zhang, C., & Lu, L. (2022) · Chemistry & Biodiversity · doi:10.1002/cbdv.202200401 · Cited by 26
Metabolic dysfunction-associated steatotic liver disease: Recent turning points for its diagnosis and management
Pοlyzos, S. A., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155936 · Cited by 25
Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease
Jokinen, M. J., & Luukkonen, P. K. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.02.003 · Cited by 27
American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults With Type 2 Diabetes – 2026 Update
Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 29
Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease
Raschi, E., Mazzotti, A., Poluzzi, E., Ponti, F. D., & Marchesini, G. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1531126 · Cited by 27
Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease
Brown, E. E., Hydes, T., Hamid, A., & Cuthbertson, D. J. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.07.013 · Cited by 25
A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosis
Sakuma, T., Nakamura, M., Chiba, T., Iwanaga, T., Kan, M., Kojima, R., Ao, J., Ma, Y., Unozawa, H., Fujita, N., et al. (2022) · Laboratory Investigation · doi:10.1038/s41374-022-00807-6 · Cited by 24
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials
An, J., & Sohn, J. H. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0437 · Cited by 24
Novel Thiazolidinedione and Rhodanine Derivatives Regulate Glucose Metabolism, Improve Insulin Sensitivity, and Activate the Peroxisome Proliferator-Activated γ Receptor
AlNeyadi, S. S., Adem, A., Amir, N., Ghattas, M. A., Abdou, I. M., & Salem, A. A. (2024) · ACS Omega · doi:10.1021/acsomega.3c07149 · Cited by 24
PPARα is one of the key targets for dendrobine to improve hepatic steatosis in NAFLD
Xu, Y., Wang, M., Luo, Y., Liu, H., Ling, H., He, Y., & Lu, Y.-L. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117684 · Cited by 23
Clinical Guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on Non-Alcoholic Fatty Liver Disease
Ivashkin, V. T., Drapkina, O. M., Maevskaya, M. V., Raikhelson, K. L., Okovityi, S. V., Жаркова, М. С., Grechishnikova, V. R., Abdulganieva, D. I., Alekseenko, S. A., Ardatskaya, M. D., et al. (2025) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2025-35-1-94-152 · Cited by 29
Treating fatty liver disease by modulating mitochondrial pyruvate metabolism
Colca, J. R., McDonald, W. G., McCommis, K. S., & Finck, B. N. (2017) · Hepatology Communications · doi:10.1002/hep4.1036 · Cited by 23
Thiazolidinediones and Glucagon‐Like Peptide‐1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study
Dalem, J. D. R.-V., Driessen, J. H. M., Burden, A. M., Stehouwer, C. D. A., Klungel, O. H., de Vries, F., & Brouwers, M. C. G. J. (2021) · Hepatology · doi:10.1002/hep.32012 · Cited by 24
Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials
Chen, J. Y. S., Chua, D., Lim, C. O., Ho, W. X., & Tan, N. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010158 · Cited by 24
NAFLD and type 2 diabetes: A practical guide for the joint management
Genua, I., Iruzubieta, P., Rodríguez-Duque, J. C., Pérez, A., & Crespo, J. (2022) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2022.12.002 · Cited by 23
Exploring the links between types 2 diabetes and liver‐related complications: A comprehensive review
Sanchez, L. O., Chen, Y., Lassailly, G., & Qi, X. (2023) · United European Gastroenterology Journal · doi:10.1002/ueg2.12508 · Cited by 26
Tissue-specific activation of insulin signaling as a potential target for obesity-related metabolic disorders
Okuma, H., & Tsuchiya, K. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108699 · Cited by 23
The impact of metabolic dysfunction-associated steatotic liver disease (MASH) on the high risk of cardiovascular disease in CKD: interconnections and management
Moncho, F., Benlloch, S., & Górriz, J. L. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf260 · Cited by 25
Beyond Discrete Diagnoses: Conceptualizing Obesity-associated Metabolic Disorders as a Unified, Dynamic Continuum
Xie, C., Yuan, Y., Wang, Y., Qi, C., Wang, W., An, C., Aikepaer, A., Zhang, Y., Zhang, G., Feng, X., et al. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00673-5 · Cited by 28
Multi-drug approaches to NASH: what’s in the development pipeline?
Johnston, M. P., Patel, J., & Byrne, C. D. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1668926 · Cited by 22
Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction
Mathews, S. E., Kumar, R. B., & Shukla, A. P. (2018) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000432 · Cited by 23
A structured literature review of interventions used in the management of nonalcoholic steatohepatitis ( NASH )
Povsic, M., Oliver, L., Jiandani, N. R., Perry, R., & Bottomley, J. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.485 · Cited by 22
Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in Mice
van den Hoek, A. M., Pieterman, E. J., van der Hoorn, J. W., Iruarrizaga‐Lejarreta, M., Alonso, C., Verschuren, L., Skjæret, T., Princen, H. M. G., & Fraser, D. A. (2019) · Hepatology Communications · doi:10.1002/hep4.1453 · Cited by 22
Role of amino acids in the regulation of hepatic gluconeogenesis and lipogenesis in metabolic dysfunctionassociated steatotic liver disease
Kakazu, E., Mino, M., & Kanto, T. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0048 · Cited by 24
Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?
Perdomo, C. M., Garcı́a-Fernández, N., & Escalada, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10092040 · Cited by 21
Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Euh, W., Lim, S. K., & Kim, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.613389 · Cited by 23
Anti-diabetic drugs and NASH: from current options to promising perspectives
Smati, S., Canivet, C. M., Boursier, J., & Cariou, B. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1951701 · Cited by 21
Nonalcoholic Fatty Liver Disease.
Ding, L.-L., Oligschlaeger, Y., Shiri-Sverdlov, R., & Houben, T. (2020) · Handbook of Experimental Pharmacology · doi:10.1007/164_2020_352 · Cited by 4
Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Review and Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
Bae, J., Han, E., Lee, H. W., Park, C., Chung, C. H., Lee, D. H., Cho, E. H., Rhee, E., Yu, J. H., Park, J. H., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0541 · Cited by 23
New Therapeutic Approaches for the Treatment of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Increased Cardiovascular Risk
Branković, M., Dukić, M., Gmizić, T., Popadić, V., Nikolić, N., Sekulic, A. D., Brajković, M., Đokić, J., Mahmutović, E., Lasica, R., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14020229 · Cited by 21
Making Sense of the Nonalcoholic Fatty Liver Disease Clinical Practice Guidelines: What Clinicians Need to Know
Cusi, K. J., Budd, J., Johnson, E. L., & Shubrook, J. H. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0014 · Cited by 20
Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis
Sayıner, M., Lam, B. P., Golabi, P., & Younossi, Z. M. (2018) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284818811508 · Cited by 20
No More NAFLD: The Term Is Now MASLD
Bae, J. C. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.103 · Cited by 23
Nonalcoholic steatohepatitis: A comprehensive updated review of risk factors, symptoms, and treatment
Savari, F., & Mard, S. A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28468 · Cited by 21
A Review of the Epidemiology, Pathophysiology, and Efficacy of Anti-diabetic Drugs Used in the Treatment of Nonalcoholic Fatty Liver Disease
Manka, P. P., Kaya, E., Canbay, A. E., & Syn, W. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-07206-9 · Cited by 22
NAFLD as the metabolic hallmark of obesity
Rojano‐Toimil, A., Sena, E., Manzano-Núñez, R., Pericàs, J. M., & Ciudin, A. (2022) · Internal and Emergency Medicine · doi:10.1007/s11739-022-03139-x · Cited by 22
Anti-Diabetic Medications for the Pharmacologic Management of NAFLD
Cholankeril, R. T., Patel, V., Perumpail, B. J., Yoo, E. R., Iqbal, U., Sallam, S., Shah, N. D., Kwong, W., Kim, D., & Ahmed, A. (2018) · Diseases · doi:10.3390/diseases6040093 · Cited by 21
Management of NAFLD patients with advanced fibrosis
Maya‐Miles, D., Ampuero, J., Gallego‐Durán, R., D’Ingianna, P., & Romero‐Gómez, M. (2021) · Liver International · doi:10.1111/liv.14847 · Cited by 19
Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management
Adinolfi, L. E., Marrone, A., Rinaldi, L., Nevola, R., Izzi, A., & Sasso, F. C. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001281 · Cited by 18
First identification and pathogenicity study of Vibrio harveyi isolated from diseased American eel ( Anguilla rostrata ) cultivated in freshwater
Wan, Q., Wu, L., Yang, Q., Lin, M., & Guo, S. (2021) · Aquaculture Research · doi:10.1111/are.15658 · Cited by 18
Non-Alcoholic Fatty Liver Disease and Extrahepatic Cancers: A Wolf in Sheep’s Clothing?
Mitsala, A., Tsalikidis, C., Romanidis, Κ., & Pitiakoudis, M. S. (2022) · Current Oncology · doi:10.3390/curroncol29070356 · Cited by 22
Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status
Mahtab, M. A., Akbar, S. M. F., Roy, P. P., Rahim, M. A., Yesmin, S. M. S., & Islam, S. B. (2022) · Euroasian Journal of Hepato-Gastroenterology · doi:10.5005/jp-journals-10018-1360 · Cited by 18
The Interlink Between Metabolic-Associated Fatty Liver Disease and Polycystic Ovary Syndrome
Vidal‐Cevallos, P., Mijangos-Trejo, A., Uribe, M., & Chávez-Tapia, N. C. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2023.01.005 · Cited by 18
Metabolic dysfunction associated steatotic liver disease: Current practice, screening guidelines and management in the primary care setting
Gupta, U., Ruli, T. M., Buttar, D., Shoreibah, M., & Gray, M. E. (2023) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2023.11.007 · Cited by 19
The effect of thiazolidinediones on body fat redistribution in adults: A systematic review and meta‐analysis of randomized controlled trials
Zhang, F., Pan, X., Zhang, X., & Tong, N. (2023) · Obesity Reviews · doi:10.1111/obr.13675 · Cited by 19
Current treatment options for nonalcoholic fatty liver disease
Shetty, A., & Syn, W. (2019) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000528 · Cited by 19
Novel targeted therapies for the management of liver fibrosis
Trivella, J. P., Martin, P. B., & Carrion, A. F. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1735350 · Cited by 19
Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis
Shi, Y., & Fan, J. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00822-1 · Cited by 19
FGF-21 analogues for treatment of non-alcoholic steatohepatitis and fibrosis: a meta-analysis with fragility index of phase 2 randomised placebo-controlled trials
Mantovani, A., Tilg, H., & Targher, G. (2023) · Gut · doi:10.1136/gutjnl-2023-331115 · Cited by 18
Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma
Cernea, S., & Onișor, D. M. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i2.286 · Cited by 18
Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative
Stokman, G., van den Hoek, A. M., Thorbek, D. D., Pieterman, E. J., Veidal, S. S., Basta, B. N., Iruarrizaga‐Lejarreta, M., van der Hoorn, J. W., Verschuren, L., Berbée, J. F. P., et al. (2020) · Liver International · doi:10.1111/liv.14643 · Cited by 17
Fibrosis Development Linked to Alterations in Glucose and Energy Metabolism and Prooxidant–Antioxidant Balance in Experimental Models of Liver Injury
Semenovich, D. S., Andrianova, N. V., Zorova, L. D., Pevzner, I. B., Abramicheva, P. A., Elchaninov, A. V., Маркова, О. В., Petrukhina, A. S., Zorov, D. B., & Plotnikov, E. Y. (2023) · Antioxidants · doi:10.3390/antiox12081604 · Cited by 14
Markers of adipose tissue fibrogenesis associate with clinically significant liver fibrosis and are unchanged by synbiotic treatment in patients with NAFLD
Bilson, J., Oquendo, C. J., Read, J., Scorletti, E., Afolabi, P. R., Lord, J., Bindels, L. B., Targher, G., Mahajan, S., Baralle, D., et al. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155759 · Cited by 16
NASH (nonalcoholic steatohepatitis), diabetes, and macrovascular disease: multiple chronic conditions and a potential treatment at the metabolic root
Colca, J. R. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1715940 · Cited by 17
Pre-Diabetes-Linked miRNA miR-193b-3p Targets PPARGC1A, Disrupts Metabolic Gene Expression Profile and Increases Lipid Accumulation in Hepatocytes: Relevance for MAFLD
Mollet, I. G., & Macedo, M. P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043875 · Cited by 16
Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case–control study
Chang, K., Kuo, F.-C., Yang, C., Yang, C.-T., Ou, H., & Kuo, S. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02461-2 · Cited by 17
Role of anti-diabetic medications in the management of MASLD
Isaacs, S. D., Farrelly, F. V., & Brennan, P. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2024-102856 · Cited by 19
Antifibrotic Effects of the Thiazolidinediones in Eosinophilic Esophagitis Pathologic Remodeling: A Preclinical Evaluation
Nhu, Q. M., Hsieh, L. Y., Dohil, L., Dohil, R., Newbury, R., Kurten, R. C., Moawad, F. J., & Aceves, S. S. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000164 · Cited by 15
Approach to the Patient With Nonalcoholic Fatty Liver Disease
Belfort‐DeAguiar, R., Lomonaco, R., & Cusi, K. J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac624 · Cited by 16
The association between changes in hepatic steatosis and hepatic fibrosis with cardiovascular outcomes and mortality in patients with New-Onset type 2 Diabetes: A nationwide cohort study
Park, J., Kim, G., Kim, B., Han, K., Kwon, S. Y., Park, S., Lee, Y., Jin, S., & Kim, J. H. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110191 · Cited by 15
Ipragliflozin and sodium glucose transporter 2 inhibitors to reduce liver fat: will the prize we sought be won?
Pafili, K., Maltezos, E. S., & Παπάνας, Ν. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1413346 · Cited by 15
Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazar
Grobbee, E. J., de Jong, V., Schrieks, I. C., Tushuizen, M. E., Holleboom, A. G., Tardif, J., Lincoff, A. M., Schwartz, G. G., Cabezas, M. C., & Grobbee, D. E. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277706 · Cited by 14
Retracted
Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review
Torosian, K., Lal, E., Kavanaugh, A., Loomba, R. S., Ajmera, V. H., & Gumá, M. (2023) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2023.152165 · Cited by 15
Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study
Fu, J., Wanxia, X., Gao, X., Xu, J., Wenjuan, Y., Jianrong, L., He, Q., Ma, K., Lian, J., Taixiong, C., et al. (2023) · Journal of Diabetes Research · doi:10.1155/2023/2044090 · Cited by 14
Two sides of the same coin: Non-alcoholic fatty liver disease and atherosclerosis
Zhu, B., Wu, H., Li, K. S., Eisa-Beygi, S., Singh, B., Bielenberg, D. R., Huang, W., & Chen, H. (2023) · Vascular Pharmacology · doi:10.1016/j.vph.2023.107249 · Cited by 14
Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
Bril, F., Berg, G. A., Barchuk, M., & Nogueira, J. P. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.1.5 · Cited by 15
Trends in pioglitazone use among U.S. adults with type 2 diabetes and suspected nonalcoholic fatty liver disease
Le, P., Chaitoff, A. M., Rothberg, M. B., McCullough, A. J., & Alkhouri, N. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1704731 · Cited by 13
Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective
Ramadan, M. S., Russo, V., Nigro, G., Durante‐Mangoni, E., & Zampino, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081569 · Cited by 15
A Review of Liver Fibrosis and Emerging Therapies
Nathwani, R., Mullish, B. H., Kockerling, D., Forlano, R., Manousou, P., & Dhar, A. (2020) · European Medical Journal · doi:10.33590/emj/10310892 · Cited by 13
Therapeutic developments in metabolic dysfunction-associated fatty liver disease
Shi, Y., & Fan, J. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002091 · Cited by 14
Insulin sensitizers in 2023: lessons learned and new avenues for investigation
Colca, J. R., Tanis, S. P., Kletzien, R. F., & Finck, B. N. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2263369 · Cited by 13
An Egg White-Derived Peptide Enhances Systemic Insulin Sensitivity and Modulates Markers of Non-Alcoholic Fatty Liver Disease in Obese, Insulin Resistant Mice
Zani, S. C. D. C., Wang, R., Veida-Silva, H., Clugston, R. D., Yue, J. T. Y., Mori, M. A. S., Wu, J., & Chan, C. B. (2023) · Metabolites · doi:10.3390/metabo13020174 · Cited by 14
Mixed micelles loaded with the 5-benzylidenethiazolidine-2,4-dione derivative SKLB023 for efficient treatment of non-alcoholic steatohepatitis
Li, Y., Zhang, T., Liu, Q., Zhang, J., Li, R., Pu, S., Wu, T., Ma, L., & He, J. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s202821 · Cited by 13
Therapeutic Potential of Peroxisome Proliferator-Activated Receptor Modulation in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
Gellrich, L., & Merk, D. (2017) · Nuclear Receptor Research · doi:10.11131/2017/101310 · Cited by 13
Should the new EASL–EASD–EASO Clinical Practice Guidelines on MASLD recommend pioglitazone as a MASH-targeted pharmacotherapy?
Júnior, W. S. D. S., Sposito, A. C., & Godoy‐Matos, A. F. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.034 · Cited by 12
Breakthrough in the Treatment of Metabolic Associated Steatotic Liver Disease: Is it all over?
Petroni, M. L., Perazza, F., & Marchesini, G. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.04.021 · Cited by 13
Impact of Metabolic Dysfunction–associated Steatotic Liver Disease on Cardiovascular Structure, Function, and the Risk of Heart Failure
Bansal, B., Lajeunesse‐Trempe, F., Keshvani, N., Lavie, C. J., & Pandey, A. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.04.012 · Cited by 15
Nonalcoholic Fatty Liver Disease and Implications for Older Adults with Diabetes
Mantovani, A., Targher, G., & Zoppini, G. (2020) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2020.04.010 · Cited by 12
Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes
Yang, J. Y., Moon, A. M., Kim, H. H., Pate, V., Barritt, A. S., Crowley, M. J., Buse, J. B., Stürmer‎, T., & Alexopoulos, A. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107706 · Cited by 12
An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents
Rubin, V. R., Bojanić, K., Smolić, M., Rubin, J., Tabll, A. A., & Smolić, R. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00040 · Cited by 12
Progress in promising anti-fibrotic therapies
Santoro, R., & Mangia, A. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1688659 · Cited by 12
Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Facts and Hopes
Adinolfi, L. E., Marrone, A., Izzi, A., & Craxì, A. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103411 · Cited by 11
Pioglitazone with SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes and non-alcoholic fatty liver disease: could the combinations of an old friend with new players yield better outcomes?
Papaetis, G. S., Picolos, M. K., & Sacharidou, A. (2025) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/202298 · Cited by 12
A Network Pharmacology Study on the Active Components and Targets of the Radix Ginseng and Radix Bupleuri Herb Pair for Treating Nonalcoholic Fatty Liver Disease
Zhang, Q., Zhang, L., Liu, K., Shang, H., Ruan, J., Yu, Z., Meng, S., Liang, F., Wang, T., Zhang, H., et al. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/1638740 · Cited by 11
Tratamiento actual de la enfermedad por hígado graso no alcohólico
Moctezuma‐Velázquez, C. (2018) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2017.10.003 · Cited by 11
Therapy to Obese Type 2 Diabetes Mellitus: How Far Will We Go Down the Wrong Road?
Heng, X.-P., Li, X., Li, L., Yang, L., Wang, Z.-T., & Huang, S.-P. (2018) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-018-3053-8 · Cited by 11
Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver
Leiva, E. G., & Bril, F. (2020) · Current Hypertension Reviews · doi:10.2174/1573402116999201209203534 · Cited by 11
Roles of nuclear receptors in hepatic stellate cells
Pu, S., Zhou, H., Liu, Y., Liu, J., Guo, Y., & Zhou, H. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1949288 · Cited by 12
Diagnosis and Management of MASLD: An Metabolic Perspective of a Multisystem Disease
Ganakumar, V., Halebidu, T., Goroshi, M., & Ghatnatti, V. (2024) · International journal of clinical metabolism and diabetes. · doi:10.1177/30502071231220779 · Cited by 10
NAFLDkb: A Knowledge Base and Platform for Drug Development against Nonalcoholic Fatty Liver Disease
Xu, T., Gao, W., Zhu, L., Chen, W., Niu, C., Yin, W., Ma, L., Zhu, X., Ling, Y., Gao, S., et al. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00395 · Cited by 11
Potential therapeutic medicines for renal fibrosis: Small-molecule compounds and natural products
Yu, X., Yuan, Z., Deng, Q., Xie, L., Yu, D., & Shi, J. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106999 · Cited by 10
Impact of Genetic Polymorphism on Response to Therapy in Non-Alcoholic Fatty Liver Disease
Martínez‐Montoro, J. I., Cornejo-Pareja, I. M., Gómez‐Pérez, A. M., & Tinahones, F. J. (2021) · Nutrients · doi:10.3390/nu13114077 · Cited by 11
Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents
García‐Compeán, D., Kumar, R., del Cueto-Aguilera, Á. N., Maldonado-Garza, H. J., & Villarreal‐Pérez, J. Z. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100751 · Cited by 10
Comprehensive assessment of the causal effects and metabolite mediators of glucose-lowering drug targets on cardio-renal-liver-metabolic health
Huang, H., Ruan, H., Lu, X., Chen, S., Chen, J., Tan, N., Pan, W., Liu, J., & Liu, Y. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156276 · Cited by 10
Thiazolidinediones (TZDs)
Won, J. C. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_11 · Cited by 9
A Quantitative Systems Pharmacology Platform Reveals NAFLD Pathophysiological States and Targeting Strategies
Lefever, D. E., Miedel, M. T., Pei, F., DiStefano, J. K., DeBiasio, R., Shun, T. Y., Saydmohammed, M., Chikina, M. D., Vernetti, L. A., Soto–Gutiérrez, A., et al. (2022) · Metabolites · doi:10.3390/metabo12060528 · Cited by 12
Risk Prevention and Health Promotion for Non-Alcoholic Fatty Liver Diseases (NAFLD)
Khan, A., Ross, H. M., Parra, N. S., Chen, S. L., Chauhan, K., Wang, M., Yan, B. M., Magagna, J., Beiriger, J., Shah, Y., et al. (2022) · Livers · doi:10.3390/livers2040022 · Cited by 9
Mitochondrial targeted therapies in MAFLD
Lai, S., Tang, D., & Feng, J. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151498 · Cited by 10

Authors: Musso, G., Cassader, M., Paschetta, E., & Gambino, R.
Affiliations: Ospedale Humanitas Gradenigo (IT)
University of Turin (IT)
Corresponding author: Musso, Giovanni
ORCID: Musso, Giovanni
Gambino, Roberto
Venue: JAMA Internal Medicine
Publisher: American Medical Association (AMA)
Published: 2017-05-01
Volume: 177
Issue: 5
Pages: 633
ISSN: 2168-6106 (ISSN-L)
DOI: 10.1001/jamainternmed.2016.9607
PMC: PMC5470366
OpenAlex: W2593506275
Cited by: 449
References: 31
Citations by year: 2026: 37 · 2025: 49 · 2024: 45 · 2023: 69 · 2022: 58 · 2021: 66 · 2020: 39 · 2019: 33 · 2018: 32 · 2017: 18
FWCI: 26.12
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: JAMA Internal Medicine (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords: thiazolidinediones, nonalcoholic steatohepatitis, advanced liver fibrosis, pioglitazone, rosiglitazone, NASH resolution, adverse drug reactions, weight gain, congestive heart failure, anemia, drug safety, liver transplantation risk, risk of bias assessment, risk of bias
MeSH terms: Pioglitazone, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Treatment Outcome, Disease Progression, Thiazolidinediones, Non-alcoholic Fatty Liver Disease, Protective Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks